Testing 8M2D in healthy people and Alzheimer's patients
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new drug called 8M2D in two groups: healthy volunteers and people with early Alzheimer's disease. The goal is to check if the drug is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For healthy volunteers: aged 18-55 years
- For Alzheimer's group: aged 55-80 years with early Alzheimer's disease
- Body mass index (BMI) between 18 and 32, weighing at least 50 kg (110 lbs)
- Generally healthy, without major medical conditions
- Non-smokers (no nicotine in the past 3 months for healthy group)
- Agree to use contraception during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new investigational drug, BMS-986446, given as a single dose to healthy volunteers and multiple doses to people with early Alzheimer's disease. It aims to understand how the drug moves in the body, its safety, and whether it triggers an immune response, which could help guide future treatment for Alzheimer's.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
This trial tests an investigational drug called DNL921 in healthy volunteers and in people with mild to moderate Alzheimer's disease. The goal is to see if it is safe and how the body handles it, which is a first step in finding a new treatment.
This study tests whether a new drug called Latrepirdine (DMB-I) is safe and effective for people with mild to moderate Alzheimer's dementia. It may help slow cognitive decline when added to current treatment or used alone.
This trial tests an experimental drug, DNL628, to see if it is safe and how it affects people with early Alzheimer's disease. It may help slow the disease by targeting a specific process in the brain.
This early-stage trial tests a new medicine called GSM-779690T in healthy volunteers to see how safe it is and how the body handles it. Participating could help determine if the medicine is worth testing in people with certain conditions later.
Hear when a new Alzheimer's Disease (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.